EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Observational cohort study of long‐term outcomes of liver transplantation in haemophilia

Margaret V Ragni iD, Jessica Callis iD, Nabil Daoud, Brian Hu, Matthew Manuel iD, Jarren Santos iD, Jonathan Schwartz iD, Kenneth D Friedman iD, Peter Kouides iD, Philip Kuriakose iD, Andrew D Leavitt iD, Ming Y Lim iD und 3 weitere

Haemophilia · 2024

DOI: 10.1111/hae.14910 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Haemophilia, 2024. Verfasst von Margaret V Ragni und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, and Hemophilia Center of Western PA, Pittsburgh, Pe…. Hauptthemen laut MEDLINE: Hemophilia A, Liver Transplantation, HIV Infections, Hemophilia B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BioMarin Pharmaceutical External Research Program, BioMarin Pharmaceutical, HRSA Subaward Region III Federal Hemophilia Treatment Centers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gene therapy is now a reality for individuals with haemophilia, yet little is known regarding the quality‐of‐life impact of factor correction. As few data exist, and recognizing the analogy to liver transplantation (OLTX), we identified OLTX+ and OLTX‐ men in the ATHNdataset to compare post‐OLTX factor VIII and IX on quality of life (QoL) by Haem‐A‐QoL and PROMIS‐29.

Methods

OLTX‐ were matched to OLTX+ by age, race, and haemophilia type and severity. Deidentified demographic data, including post‐transplant factor levels, genotype and target joint disease were analysed by descriptive statistics. Haem‐A‐Qol and PROMIS‐29 were compared in OLTX+ and OLTX‐ by student's t ‐test and univariate regression models.

Results

Of 86 people with haemophilia A (HA) or haemophilia B (HB) cared for at 10 haemophilia treatment centers (HTCs), 21 (24.4%) OLTX+ and 65 (75.6%) OLTX‐ were identified. OLTX+ and OLTX‐ had a similar frequency of target joint disease ( p = .806), HA genotypes, null versus non‐null ( p = .696), and HIV infection ( p = .316). At a median 9.2 years post‐OLTX, median FVIII, .63 IU/mL [IQR 0.52–0.97] and FIX, .91 IU/mL [IQR .63–1.32], Haem‐A‐QoL, PROMIS‐29, and HOT scores were comparable. Severe HA/HB had lower post‐OLTX ‘dealing with haemophilia’ scores ( p = .022) and higher ‘sports and leisure’ ( p = .010) and ‘view of yourself’ scores ( p = .024) than OLTX+ non‐severe participants. Non‐caucasian OLTX+ had significantly lower scores in sports and leisure ( p = .042), future expectations ( p = .021) and total score ( p = .010).

Conclusion

Nine years after OLTX, QoL is comparable to OLTX–, but significantly better in OLTX+ with severe than non‐severe disease and in caucasians than non‐caucasians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia ALiver TransplantationHIV InfectionsHemophilia BJoint DiseasesMaleHumansQuality of LifeCohort StudiesHeme

Stichwörter der Autor:innen

factorgene therapyhemophilialiver diseaseliver transplantationoutcomes researchquality of life

Substanzen

Heme

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, and Hemophilia Center of Western PA, Pittsburgh, Pennsylvania, USA.
  • American Thrombosis Hemostasis Network, Rochester, New York, USA.
  • Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin, USA.
  • Mary M. Gooley Hemophilia Center, Rochester, New York, USA.
  • Henry Ford Health System Bleeding and Thrombosis Center, Detroit, Michigan, USA.
  • San Francisco Hemophilia Treatment Center, University of California, San Francisco, California, USA.

ORCID-Profile: Margaret V Ragni, Jessica Callis, Matthew Manuel, Jarren Santos, Jonathan Schwartz, Kenneth D Friedman, Peter Kouides, Philip Kuriakose, Andrew D Leavitt, Ming Y Lim, Nicoletta Machin, Michael Recht, Tammuella Chrisentery-Singleton

Förderung

  • BioMarin Pharmaceutical External Research Program
  • BioMarin Pharmaceutical
  • HRSA Subaward Region III Federal Hemophilia Treatment Centers
  • PA-DOH State Support of Hemophilia Center of Western Pennsylvania
  • Pennsylvania Department of Health

Zitieren

APA

Ragni, M. V., Callis, J., Daoud, N., Hu, B., Manuel, M., Santos, J., Schwartz, J., Friedman, K. D., Kouides, P., Kuriakose, P., Leavitt, A. D., Lim, M. Y., Machin, N., Recht, M., & Chrisentery-Singleton, T. (2024). Observational cohort study of long‐term outcomes of liver transplantation in haemophilia. Haemophilia. https://doi.org/10.1111/hae.14910

Vancouver

Ragni MV, Callis J, Daoud N, Hu B, Manuel M, Santos J, et al. Observational cohort study of long‐term outcomes of liver transplantation in haemophilia. Haemophilia. 2024. doi:10.1111/hae.14910

BibTeX
@article{Ragni2024,
  author = {Ragni, Margaret V and Callis, Jessica and Daoud, Nabil and Hu, Brian and Manuel, Matthew and Santos, Jarren and Schwartz, Jonathan and Friedman, Kenneth D and Kouides, Peter and Kuriakose, Philip and Leavitt, Andrew D and Lim, Ming Y and Machin, Nicoletta and Recht, Michael and Chrisentery-Singleton, Tammuella},
  title = {Observational cohort study of long‐term outcomes of liver transplantation in haemophilia},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.14910}
}
Kostenlos starten →